Evidence map›Paper›PMID 34361838›Full record

ArticleMolecules (Basel, Switzerland)2021

Detection of 4a,5-dihydropravastatin as Impurity in the Cholesterol Lowering Drug Pravastatin.

Wibo B van Scheppingen, Peter P Lankhorst, Marcus Hans, Marco A van den Berg

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wibo B van ScheppingenDSM Biotechnology Center, 2613 AX Delft, The Netherlands.
Peter P LankhorstDSM Biotechnology Center, 2613 AX Delft, The Netherlands.ORCID 0000-0002-0373-5673
Marcus HansDSM Biotechnology Center, 2613 AX Delft, The Netherlands.
Marco A van den BergDSM Biotechnology Center, 2613 AX Delft, The Netherlands.ORCID 0000-0003-2770-9944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dihydro analogues are known byproducts of the fermentative production of statins and cannot be detected with existing pharmacopoeia analysis methods. We detected dihydropravastatin in most commercial formulations of pravastatin with LC-MS, in some cases in levels requiring identification. In fermentation broth samples of the single step production of pravastatin, we detected and identified for the first time 4a,5-dihydropravastatin, and confirmed that after several recrystallization steps this impurity can be fully removed from the pravastatin powder.

Indexed as

Drug ContaminationAnticholesteremic AgentsChromatography, LiquidMass SpectrometryPravastatinAnticholesteremic AgentsPravastatinactive pharmaceutical ingredientbiosynthesisdihydrostatinsfinished dosage formsmass spectrometryNMR

Identifiers

PMID34361838
PMCPMC8347671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.